ISPOR ANNOUNCES PARTNERSHIP WITH CAC

Published Aug 5, 2015
Princeton, NJ, USA and Bogota, Colombia, August 5, 2015 – The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced an agreement with CAC (High Cost Disease Fund of Colombia), an organization within the Colombia Ministry of Health, dedicated to addressing issues surrounding the significant budget impact of high cost diseases in the country.   [caption id="attachment_2157" align="alignleft" width="160"]Berg Nancy Berg[/caption] In a joint press conference yesterday, ISPOR CEO & Executive Director Nancy Berg announced that “the partnership with CAC is an important step in supporting the development of sustainable health care systems throughout Latin America.”  Berg also discussed the partnership’s alignment with ISPOR’s Strategic Plan, Vision 2020: “Vision 2020 guides the Society to collaborate with global, regional and local organizations that share a common mission.  Through this new partnership, ISPOR and CAC will collaborate with other stakeholders in developing a plan to disseminate information, educational materials and decision-making tools on health economics and outcomes research throughout the region.” ISPOR is the leading international organization dedicated to promoting health economics and outcomes research excellence to improve decision making for health globally.  Through more than 9000 members in 140 countries and an additional 9000 regional chapter members, ISPOR produces comprehensive education and training, decision-making tools and the largest meetings of health economics and outcomes professionals in Latin America, Europe, North America and Asia.  More than 80 chapters and 80 student chapters of ISPOR operate locally to ensure delivery of regionally relevant content, information to support policy development, knowledge sharing and consensus building on local topics.  There are currently 12 ISPOR Chapters throughout Latin America, including Colombia. ISPOR will hold its biennial Latin America Conference September 6-8, 2015 in Santiago, Chile.  Plenary speakers for this meeting include:
  • Jeanette Vega, MD, MPH, PhD, Director of FONASA (Chile National Health Fund);
  • Norman Daniels, PhD, Mary B. Saltonstall Professor of Population Ethics and Professor of Ethics and Population Health, Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University; and
  • Antony Culyer, Hon DEcon, Hon FRCP, FRSA, FMedSci, Ontario Research Chair in Health Policy and System Design, Institute of Health Policy, Management and Evaluation, University of Toronto.
The HTAnetLatAm, a group of health technology assessment experts from throughout the region will meet during the ISPOR Conference.  In addition, CAC, REDETSA and PAHO will also hold workshops in conjunction with the ISPOR meeting, which is gaining prominence as an educational platform as well as convener of leaders and leading organizations in health care.   ISPOR expects 1000 experts from around the world to gather in Santiago this September.  To register, visit http://www.ispor.org/Event/Index/2015Santiago. For more information on ISPOR in Latin America, contact Jerusha Harvey, Director of Development in Latin America at jharvey@ispor.org. ABOUT ISPOR COLOMBIA The ISPOR Colombia Chapter was established in July 2007. Lead by Diego Rosselli, MD, MEd, MHP, Associate Professor of Health Economics at Javeriana University, the chapter is host to regular training and information series on health economics and outcomes research. August 22, 2015 marks their launch of the Spanish version of the ISPOR publication Therapeutic and Diagnostic Device Outcomes Research. For more information contact: asistencia.ispor.co@gmail.com

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×